Trial Profile
A Multicenter, Prospective, Randomized, Open-label, Parallel Group Study to Investigate the Clinical Benefit on Hypoglycemia Frequency of 24 Weeks Treatment With Galvus Versus Usual Care (Any OAD of Another Class Added to Metformin Within SmPc) in Older Patients With Type 2 Diabetes Insufficiently Controlled by Metformin Monotherapy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Feb 2017
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary) ; Antihyperglycaemics
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms GLYCEMIA
- Sponsors Novartis
- 03 May 2012 Actual end date Dec 2011 added as reported by ClinicalTrials.gov.
- 03 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Nov 2010 New trial record